Antiglutamate therapies in Huntington's disease

Journal of Neural Transmission, Supplement

Volumn , Issue 55, 1999, Pages 97-102

  Kieburtz, K ^a  

^a UNIVERSITY OF ROCHESTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENINE; CYTOSINE; FREE RADICAL; GLUTAMATE RECEPTOR ANTAGONIST; GLUTAMIC ACID; GUANINE; PLACEBO; REMACEMIDE; TRINUCLEOTIDE; UBIDECARENONE; ACETAMIDE DERIVATIVE; AMINO ACID RECEPTOR BLOCKING AGENT; NEUROPROTECTIVE AGENT;

ARTICLE; AUTOSOMAL DOMINANT DISORDER; BRAIN MITOCHONDRION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEGENERATIVE DISEASE; HUMAN; HUNTINGTON CHOREA; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TRINUCLEOTIDE REPEAT; DOMINANT GENE; GENETICS; REVIEW;

ACETAMIDES; EXCITATORY AMINO ACID ANTAGONISTS; GENES, DOMINANT; HUMANS; HUNTINGTON DISEASE; NEUROPROTECTIVE AGENTS; TRINUCLEOTIDE REPEATS;

EID: 0032589193     PISSN: 03036995     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-7091-6369-6_9     Document Type: Article

References (32)

1. Albin RL, Young AB, Penney JB (1989) The functional anatomy of basal ganglia disorders. Trends Neurosci 12: 366-375
2. Albin RL, Young AB, Penney JB, Handelin B, Balfour R, Anderson KD, Markel DS, Tourtellotte WW, Reiner A (1990) Abnormalities of striatal projection neurons and N-methyl-D-aspartate receptors in presymptornatic Huntington's disease. N Engl J Med 332: 1293-1298
3. Bamford KA, Caine ED, Kido DR, Plassche WM, Shoulson I (1989) Clinical-pathologic correlation in Huntington's disease: A neuropsychological and computed tomography study. Neurology 39: 796-801
4. Beal MF, Kowall NW, Ellison DW, Mazurek MF, Swartz KJ, Martin JB (1986) Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid. Nature 321: 168-171
5. Beal MF, Ferrante RJ, Swartz KJ, Kowall NW (1991) Chronic quinolinic acid lesions in rats closely resemble Huntington's disease. J Neurosci 11: 1649-1659
6. Beal W, Brouillet E, Jenkins BG, Ferrante RJ, Kowall NW, Miller JM, Storey E, Srivastava R, Rosen BR, Hyman BT (1993a) Neurochemical and histological characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. J Neurosci 13: 4181-4192
7. Beal MF, Brouillet E, Jenkins BG, Henshaw R, Rosen B, Hyman BT (1993b) Age-dependent striatal excitotoxic lesions produced by the endogenous mitochondrial inhibitor malonate. J Neurochem 61: 1147-1150
8. Beal MF, Henshaw DR, Jenkins BG, Rosen BR, Schulz JB (1994) Coenzyme Q10 and nicotinamide block striatal lesions produced by the mitochondrial toxin malonate. Ann Neurol 36: 882-888
9. Brandt J (1991) The Hopkins verbal learning test: development of a new memory test with six equivalent forms. Clin Neuropsychol 5: 125-142
10. Choi DW (1988) Glutamate neurotoxicity and diseases of the nervous system. Neuron 1: 623-634
11. Coyle JT, Schwarcz R (1976) Lesion of striatal neurons with kainic acid provides a model for Huntington's chorea. Nature 263: 244-246
12. Feigin A, Kieburtz K, Bordwell K, Como P, Steinberg K, Sotack J, Zimmerman C, Hickey C, Orme C, Shoulson I (1995) Functional decline in Huntington's disease. Mov Disord 10:211-214
13. Graveland GA, Williams RS, DiFiglia M (1985) Evidence of degenerative and regenerative changes in neostriatal spiny neurons in Huntington's disease. Science 227: 770-773
14. Greenamyre JT, Shoulson I (1994) Huntington's Disease. In: Calne DB (ed) Neurodegenerative disease. Saunders, Philadelphia, pp 685-704
15. Greene JG, Porter MP, Eller RV, Greenamyre JT (1993) Inhibition of succinate dehydrogenase by malonic acid produces an "excitotoc" lesion in rat striatum. J Neurochem 61: 1151-1154
16. The Huntington's Disease Collaborative Research Group (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72: 971-983
17. The Huntington Study Group (1996) Unified Huntington's Disease Rating Scale: Reiliability and Consistency. Mov Disord 11: 136-142
18. Kieburtz K, Feigin A, McDermott M, Como P, Abwender D, Zimmerman C, Hickey C, Orme C, Claude K, Sotack J, Greenamyre JT, Dunn C, Shoulson I (1996) A controlled trial of the glutamate antagonist remacemide hydrochloride in Huntington's disease. Mov Disord 11: 273-277
19. th International Meeting of the World Federation of Neurology Research Group on Huntington's Disease 8/30-9/2/97 (abstract)
20. Landwehrmeyer GB, Standaert DG, Testa CM, Penney JB, Young AB (1994) NMDA receptor subunit expression by rat striatal projection neurons and intemeurons. J Neurosci 14: 5297-5308
21. Myers RH, Sax DS, Koroshetz WJ, Mastromauro C, Cupples LA, Kiely DK, Pettengill FK, Bird ED (1991) Factors associated with slow progression in Huntington's disease. Arch Neurol 48: 800-804
22. Penney JB Jr, Young AB, Shoulson I, Starosta-Rubenstein S, Snodgrass SR, Sanchez Ramos J, Ramos-Arroyo M, Gomez F, Penchaszadeh G, Alvir J, Esteves J, DeQuiroz I, Marsol N, Moreno H, Conneally PM, Bonilla E, Wexler NS (1990) Huntington's disease in Venezuela: 7 years of follow-up on symptomatic and asymptomatic individuals. Mov Disord 5: 93-99
23. Petrides M (1990) Nonspalial conditional learning impaired in patients with unilateral frontal but not unilateral temporal lobe excisions. Neuropsychologia 28: 137-149
24. Porter RHP, Greenamyre JT (1995) Regional variations in the pharmacology of NMDA receptor channel blockers: implications for therapeutic potential. J Neurochem 64: 614-623
25. Reitan RM, Wolfson D (1958) The Halstead-Reitan Neuropsychological Test Batttery. Neuropsychology Press, Tucson
26. Schretlen D, Bobholz JH, Brandt J (1996) Development and psychometric properties of the Brief Test of Attention. Clin Neuropsychol 10: 80-89
27. Schwarcz R, Whetsell WO, Mangano RM (1982) Quinolinic acid: An endogenous metabolite that produces axon-sparing lesions in rat brain. Science 219: 316-318
28. Shoulson I, Kurlan R, Rubin AJ, Goldblatt D, Behr J, Miller C, Kennedy J, Bamford KA, Caine ED, Kido DK, Plumb S, Odoroff C (1989a) Assessment of functional capacity in neurodegenerative movement disorders: Huntington's disease as a prototype. In: Munsat TL (ed) Quantification of neurological deficit. Butterworths, Boston, pp 271-283
29. Shoulson I, Odoroff C, Oakes D, Behr J, Goldblatt D, Caine E, Kennedy J, Miller C, Bamford K, Rubin A, Plumb S, Kurlan R (1989b) A controlled clinical trial of baclofen as protective therapy in early Huntington's disease. Ann Neurol 25: 252-259
30. Young AB, Penney JB, Starosta-Rubinstein S, Markel DS, Berent S, Giordani B, Ehrenkaufer R, Jewett D, Hichwa R (1986a) PET scan investigations of Huntington's disease: cerebral metabolic correlates of neurological features and functional decline. Ann Neurol 20: 296-303
31. Young AB, Shoulson I, Penney JB, Starosta-Rubinstein S, Gomez F, Travers H, Ramos M, Snodgrass SR, Bonilla A, Moreno H, Wexler N (1986b) Huntington's disease in Venezuela: neurological features and functional decline. Neurology 36: 244-249
32. Young AB, Greenamyre JT, Hollingsworth Z, Albin R, D'Amato C, Shoulson I, Penney JB (1988) NMDA receptor losses in pulamen from patients with Huntington's disease. Science 241: 981-983